Probiotics, Chewing Gum Found Ineffective for Pharyngitis

Share this content:
Probiotics, Chewing Gum Found Ineffective for Pharyngitis
Probiotics, Chewing Gum Found Ineffective for Pharyngitis

MONDAY, Dec. 18, 2017 (HealthDay News) -- Neither probiotics nor xylitol-based chewing gum cuts the severity of symptoms associated with pharyngitis, according to a study published in the Dec. 18 issue of CMAJ, the journal of the Canadian Medical Association.

Paul Little, M.D., from the Primary Care Group in Southampton, U.K., and colleagues randomized 1,009 patients with pharyngitis (aged 3 years and older) to no chewing gum, xylitol-based chewing gum (15 percent xylitol; five pieces daily), or sorbitol gum (five pieces daily). In addition, half of each group were also randomly assigned to receive probiotic capsules (containing 24 × 109 colony-forming units of lactobacilli and bifidobacteria) or placebo. Complete data on the primary outcome (mean self-reported severity of sore throat and difficulty swallowing [scale, 0 to 6] in the first three days) were available for 689 participants.

The researchers found that probiotics were not effective in reducing the severity of symptoms (mean severity scores, 2.75 with no probiotic versus 2.78 with probiotic; adjusted difference, −0.001; 95 percent confidence interval; −0.24 to 0.24). Similarly, neither type of chewing gum was effective (mean severity scores, 2.73 without gum, 2.72 with sorbitol gum [adjusted difference, 0.07; 95 percent confidence interval, −0.23 to 0.37] and 2.73 with xylitol gum [adjusted difference, 0.01; 95 percent confidence interval, −0.29 to 0.3]). No secondary outcomes differed significantly between groups, and there were no adverse effects reported.

"There is no reason for clinicians to advise patients to use either of these treatments for the symptomatic management of pharyngitis," conclude the authors.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »